Introduction
The notion of creating artificial vision using visual prostheses has been well represented though science fiction literature and films. When we think of retinal prostheses, we immediately think of fictional characters like The Terminator scanning across a bar to assess patrons for appropriately fitting clothing, or Star Trek's Geordi La Forge with his VISOR, a visual instrument and sensory organ replacement placed across his eyes and attached into his temples to provide him with vision. Such devices are no longer farfetched. In the past 20 years, significant research has been undertaken across the globe in the race for a "Bionic Eye". Advances in Bionic Eye research have come from improvements in the design and fabrication of multielectrode arrays (MEAs) for medical applications. MEAs are already commonplace in medicine with use in applications such as the cochlear device, cardiac pacemakers, and deep brain stimulators where interfacing with neuronal cell populations is required.
The use of MEAs for vision prostheses is currently of significant interest. For the most part, retinal prostheses have dominated the research landscape owing to the ease of access and direct contact to the retinal ganglion nerve cells. However, MEAs are also in use for direct stimulation into the optic nerve [1] . Retinal prostheses bypass the damaged photoreceptor cells within the retina and instead replace the degenerate retina with electrical stimulation to the nerve cells. Using electrical stimulation, stimulated retinal ganglion cells have been shown to elicit a percept in the form of a phosphene in blind patients [2] [3] [4] [5] [6] . Accordingly, the two diseases commonly linked to the justification for Bionic Eye research are age-related macular degeneration (AMD) and retinitis pigmentosa (RP), diseases which lead to progressive loss of photoreceptor cells and diseases where the patient has had previous vision and thus exhibits prior visual-brain pathways. At present, there has been no reliable cure for any of the retinal diseases that target the photoreceptor cells, and thus the development of prosthetic devices is a viable clinical treatment option [7] [8] [9] .
The best physical location for a retinal implant remains undecided. Although this chapter concentrates on retinal prostheses, other artificial vision devices have been investigated at sites external to the eye such as the optic nerve [10] and the visual cortex [11] . Referring back to retinal prostheses, at present there have been three sites best identified for potential implant positioning: (i) epiretinal; (ii) subretinal; and (iii) suprachoroidal. Figure 24 .1 shows a drawing of an eye, highlighting the three device positions relative to the retinal ganglion nerve cell layer. The implant sites have been selected for various reasons such as distance from the nerve cells, surgical ease and mechanical stability. The majority of clinical groups have opted for the epiretinal implantation of their Bionic Eye devices [3, [12] [13] [14] [15] [16] . The epiretinal position offers the advantage that the surgical procedure is relatively well understood and the device is closely aligned with the site it is actively stimulating. In particular, the epiretinal position aligns the device against the intact retinal ganglion cells and offers the added advantage of not having to overcome the high resistance of the Mueller glial cell seal in the external limiting membrane which is seen in the later phase of RP patients [17] . However, the epiretinal device position also has its drawbacks. In order to position the device against the retina, external fixation components are required, such as tacks. Tacking through the retina so close to the stimulated area is problematic as the trauma of the insertion of the tack is detrimental to the retinal cells below and around the tack.
The subretinal implant position also provides a close alignment of the device with the underlying neuronal population it seeks to stimulate (taking advantage of the pre-existing neuronal network, albeit in a highly reorganized manner) as well as providing a mechanically stable position of the device without the need for external fixation. However, the use of the subretinal location has been restricted by the complexity of surgery, the physical disruption of the pigment epithelium and the retina as part of positioning the device, and the limitation of space which means that the devices need to be very thin. In comparison, suprachoroidal implantation of the devices offers a mechanically stable position without the need for further fixation components or the need for wires to penetrate through the eye wall via the pars planar; however, its major limitation is that the device is positioned some distance from the nerve population it seeks to stimulate. This means that the currents required to stimulate the nerve cells of the retina are significantly higher, since the current must pass through much more tissue to reach its destination.
Across the globe, there are a number of retinal prostheses or "Bionic Eye" devices in clinical trials. Probably the most successful to date have been designed in the United States of America by the Second Sight group. The second generation device, the Argus II Retinal Prosthesis System, has achieved regulatory approval for market in Europe (CE Mark) and has proven to the FDA that its benefit outweighs the risks. This is the preliminary step towards achieving market approval in the United States of America (FDA approval). Retinal prostheses devices operate like a standard brain-machine interface (BMI). A stimulus is generated by the prosthetic device and coded into an electrical signal by its electronics (machine) which is transferred into the neural interface at the device-tissue interface ( Figure 24 .2) [18] . This is detected as a visual percept by the brain, which elicits an action by the user. Accordingly, for the most part, Bionic Eye devices share common components. The devices each require a stimulating interface comprising an MEA (or multiphotodiode array) and circuitry. Further, each requires an input source, often in the form of a visual camera and clever software and hardware to convert visual images to electrical signals capable of being transmitted to the interfacing array. Finally, each device requires a method of placement. In order to achieve such complex mechanisms, the retinal prostheses often require intraocular, extraocular, and external components. The intraocular components are usually the stimulation MEA, but some retinal prostheses also implant the microcircuit. Extraocular components include the image acquisition system, data processing components, and the power and data supplies. The extraocular components are connected to the intraocular components using either wireless or wired technology. Given the large number of investigatory MEAs for Bionic Eye devices still in the preclinical research phase, this chapter will summarize the advances of the key groups with a particular focus on those that have entered the clinical trial phase of development.
The key points of difference between the different visual prosthesis technologies highlighted in this chapter are material selection, interfacing, electrode number, and the final clinical acuity. The importance of acuity is shown in Figure 24 .3. If we consider a visual scene as a combination of pixels, it can easily be seen that the more pixels, the better the image. The goal of the Bionic Eye devices is to achieve a visual phosphene, that is, a bright "spot" relative to a stimulation (electrical, mechanical, magnetic, auditory). The phosphenes need to be distinguishable in order to build useful information, and thus the preferred outcome for a Bionic Eye prosthesis is for a single electrode to be able to generate a single, non-overlapped spot that can be used to excite a visual map similar to that achieved using individual pixels. Accordingly, if we consider one electrode as one pixel, the number of electrodes to generate useful information depends on the information. Referring to Figure 24 .3a, the displayed image requires 25 pixels. This is likely not sufficient to enable a 25 pixel/electrode system to read text, but may allow some level of unguided navigation. However, as the pixels increase to 100, 400, and 1032 (Figures 24.3b-d), it is clear that the applications increase. At 1032 pixels, it is likely that a retinal prosthesis recipient can interpret large text. Of course, it is not as simple as treating one electrode as one pixel, and thus the size of electrodes and pitch chosen to elicit a phosphene differs greatly across the clinical trial devices. Further, considerable research has been undertaken as to the best method to use the generated phosphenes to gain maximum visual capacity (i.e. edge detection, blending, illumination, and MEA stimulation strategy). Referring to Figure 24 .4, various image processing techniques may be utilized to optimize phosphenegenerated vision. Figure 24 .4a shows a variety of ways a single phosphene could be modeled relative to its peers. Figure 24 .4b illustrates the variation in which a synthetic vision prosthesis may model an environment in order to maximize visual output. In order to achieve the various visual "scenes", different filtering has been applied to the original input signal. Predictive modeling is beneficial to optimize the mechanism of using the MEA of the retinal prosthesis to drive the electrical signals through the retinal ganglion cells to generate the best representation of the image the prosthesis seeks to simulate. The predictive research, however, does not necessarily translate to the final percept pattern seen by a patient. Reports from Bionic Eye groups in clinical trial have shown some concern about the interactions between neighbouring phosphenes in terms of overlap, fading, and dominance [1, 2, [4] [5] [6] [19] [20] [21] .
Considering retinal prosthesis devices in clinical trials, the EPIRET device has 25 electrodes [22] , the Bionic Vision Australia device has 35 electrodes, the Intelligent Medical Systems device has 49 electrodes [23] , Second Sight's Argus II has 60 electrodes [3] , the Boston Retinal Group has 200 electrodes [24] , and the microphotodiodide array from Retina Implant AG has 1500 elements [6] . Putting this into context, the best reported data from the epiretinal Argus II (Second Sight) and the subretinal Retina Implant AG provide a visual acuity of 20/1260 [3] and 20/550 [5] , respectively, which remains significantly lower than the 20/200 acuity used to represent legal blindness [25] .
Electrode materials for use in multielectrode arrays for retinal stimulation
Selection of electrode materials for neural stimulation is ultimately governed by safety concerns. In other words, stimulating electrodes must effectively evoke action potentials, in the target tissue, without causing damage. The functioning of a stimulating electrode in simple terms is easily conceptualised. In most instances a current pulse is driven into the electrode causing it to become charged. This localized charge affects the environment around the electrode and can cause nearby neurons to depolarize. In this simple view, any electrically conducting material could function as a neural stimulation electrode, the only question being how much charge is needed to evoke a neural response. Of course, the reality is more complicated. Firstly, electrodes must be constructed from materials which are inherently biocompatible. Secondly, consideration needs to be given to the voltages that the electrodes will reach during stimulation pulses. On forcing charge into the surface of an electrode, the energy of the surface is changed. In electrical terms, the difference in energy between the electrode surface and its environment is described in joules per coulomb (J/C) of electrons or volts. In medical terms it is the volts that generate tissue damage.
The most frequently used predictor of safe voltage limits is the water window. The water window is the voltage range bounded by the positive and negative voltage values at which significant water splitting occurs. At high positive voltages, the surface energy of the electrode is sufficiently low that electrons are pulled from water molecules (oxidative water splitting) into the electrode surface, causing the reaction shown in Equation (24.1).
The products of this reaction are protons, which alter pH, and gaseous oxygen, which is understandably undesirable in particular in a closed environment such as the eye. When electrode voltages are sufficiently negative the surface energy is so high that electrons are forced off the electrode and into water molecules (reductive water splitting), causing the reaction shown in Equation (24.2).
Similarly, OH − ions alter pH, and gaseous hydrogen is equally undesirable inside the body. The water window is usually established using cyclic voltammetry, where an electrode of the material in question is cycled from its resting (open circuit) potential to voltages where water splitting is observed to occur in both the positive and negative voltage directions. A typical cyclic voltammogram of this nature is shown in Figure 24 . 5 Water splitting is not the only undesirable reaction that occurs at high-magnitude electrode voltages. Many biomolecules can be electrochemically degraded, chloride ions in saline solution can be oxidized according to Equation (24.3), and metal from metal electrodes can be oxidized forming metal complexes in solution. The most studied of these is oxidation of platinum to form platinum hexachloride ions according to Equation (24.4) . This reaction not only introduces a toxic foreign metal complex into the patient [27] but also results in dissolution of the electrode.
The voltage limits at which water splitting occurs are material-specific and are used to evaluate the charge injection capacity of an electrode (Q c ). Charge injection capacity carries the units of coulombs per unit area, very often µC/cm 2 or mC/cm 2 . This value represents the maximum amount of charge that can be delivered during a stimulation pulse to a cm 2 of material without electrode voltage exceeding set limits. Usually those limits are derived directly from the water window. The charge injection capacity is directly related to the electrochemical capacitance of an electrode, which is described as the rate of change of electrode charge with changing electrode voltage or C = dQ/dV (C = capacitance (F), Q = charge (C), and V = volts (V)). Simply put, an electrode with high capacitance can accommodate a large amount of charge whilst experiencing a small voltage change. Such an electrode is more likely to effectively evoke action potentials in nerve tissue whilst remaining within safe voltage limits. In classical electrochemistry, electrode processes are often defined as either Faradaic or non-Faradaic reactions. An example of a non-Faradaic reaction is double-layer capacitive charging. Initial charge injected into an electrode is accommodated by rearrangement of the electrolyte solution in the immediate vicinity of the electrode. The amount of charge that can be stored in this way is a complex function of the electrolyte, the material/ electrolyte interaction and the real surface area of the electrode. Faradaic reactions are those that result in charge transfer to or from a chemical species that exists either in the solution adjacent to the electrode or within the electrode itself. The definition "reversible Faradaic reaction" refers to a process where charge can be donated to (reduction) or withdrawn from (oxidation) a chemical species reversibly. A non-reversible Faradaic process is where the products of the electrochemical reaction are electrochemically inert, and therefore the charge donated or extracted cannot be recovered.
Some of the most important historical work on the characterization of electrodes for neural stimulation, from an electrochemistry and materials point of view, was conducted at EIC laboratories by Brummer, Turner, and Roblee [28] [29] [30] in the late 1970s and 1980s. In more recent years, Stuart Cogan, also of EIC, has carried the torch and maintained the laboratories' leading role in this field [31] [32] [33] [34] , in particular through development of iridium oxide as an electrode material. A recent review penned by Stuart Cogan [31] summarized the current leading stimulating electrode .5 Cyclic voltammograms recorded using a platinum electrode in pH 7.2 phosphate buffered saline, intended to emulate biological conditions. CVs were recorded before (gray) and after (black) removal of dissolved oxygen by purging with N 2 gas. The peaks assigned to hydrogen adsorption/desorption and reversible platinum oxide formation are indicated. Also shown are the potential limits of the water window bounded by the onset of water reduction (−0.6 V) and water oxidation (0.9 V). Image adapted from [26] .
materials in terms of charge injection capacity and voltage limits. The results of that summary are shown in Table 24 .1.
Current clinical trial materials for retinal multielectrode array electrodes
The list of materials in use as stimulating electrodes in retinal implants undergoing clinical trial currently features only platinum (Pt) and titanium nitride (TiN) [6] .
Platinum (Pt)
Platinum is well established as a biocompatible medical metal [26] . Accordingly, it is an obvious trial electrode material, and fortuitously it falls into the category of electrochemical pseudocapacitors, giving it an unusually high Q c for a bare metal. The source of the additional charge injection capacity is the well-understood electrochemically induced adsorption of hydrogen that occurs on the platinum surface in aqueous electrolyte solutions. The reaction is shown in Equation (24.5).
The reaction is an electrochemically reversible Faradaic reaction and therefore under charge-balanced conditions (such as a charge-balanced biphasic current pulse) there will be no net change in the chemical environment at the electrode surface. Platinum also enjoys a long history of success in cochlear implants and is therefore the most comprehensively tested of all the possible electrode materials. Platinum electrodes are also some of the easiest to fabricate either by machining from readily available high-purity foils or by conventional metal deposition such as electron beam evaporation. One projected problem with platinum is that the charge injection capacity (≈ 150 µC cm ) is unlikely to be high enough to be safe for very small electrodes (<100 µm) where the charge densities required for effective stimulation may be high. The most likely advance in retinal stimulation arrays is towards higher-density, higherresolution electrode arrays following the hypothesis that this will lead to increased visual acuity. This will necessitate smaller and smaller electrodes, and materials with higher charge injection capacity may be required to operate effectively and within safe voltage limits.
Titanium nitride (TiN)
Titanium nitride is a material which is introduced to an electrode surface as a post process in order to improve charge injection capacity. TiN is typically introduced by a metal sublimation technique such as sputtering of a titanium target in nitrogen-rich plasma [41] . Films are typically very thin (<5 µm), otherwise delamination of the films can occur. TiN forms into a porous film with a columnar substructure resulting in a very high ratio of real to geometric surface area. There are no Faradaic processes that occur with TiN during normal operation. The source of the high charge injection capacity is double-layer capacitance charging.
Proposed electrode materials

Iridium oxide (IrOx)
Similar to TiN, IrOx is a high charge injection capacity film introduced as a post process. There are a number of methods available for forming IrOx films including electrochemical oxidation of titanium films [36] , sputtering of titanium in an oxygen-rich plasma [34, 42] , and thermal oxidation of titanium films [38] . IrOx films are highly porous (Figure 24 .6) and exhibit very high charge injection capacity due to the surface-confined reversible redox exchange between Ir 3+ and Ir
4+
. Electron exchange between the Ir(III) and Ir(IV) oxidation states occurs at potentials around +0.6 V against an Ag/AgCl reference electrode. Consequently, the highest charge injection values are observed if the electrode is maintained with an overall positive bias to hold the electrode within the voltage range where the highest amount of Faradaic charge transfer occurs.
Diamond
Nitrogen incorporated nanocrystalline diamond films (N-UNCD), originally developed by Argonne National Laboratories, have recently surfaced as a candidate for neural stimulation [43, 44] . The material is a high-surface-area nanocrystalline (around 5 nm crystals) diamond film fused with a graphitic grain boundary, capable of carrying electrical current (Figure 24.7) . Reported charge injection values lie within a range of 160 to 300 µC cm −2 , placing N-UNCD between Pt and TiN. The biochemical stability and high adhesion of diamond films may prove to be advantageous in biomedical implants.
Polymers
Conducting polymers are currently undergoing extensive research as stimulating electrode materials. The front runner among these is poly(3,4-ethylene dioxythiophene) (PEDOT) [46] . PEDOT is electrochemically deposited directly on the electrode and can exhibit very high charge injection values (1-4 mC cm
) [46, 47] . The principal concern with conducting polymers is stability over the very long duty cycle expected of a vision prosthesis.
Interfacing systems for retinal implants
In order to generate a retinal implant system, it is critical that the interfacing between the input source (i.e. the stimulating electronics and the MEA) and the ocular tissue is appropriate. The electrodes are designed under material restrictions outlined above in Section 24.1 and often have strict requirements as to the optimal size, shape, and placement. In addition to a series of electrodes, the retinal implant systems require clever communication hardware and software to ensure that the appropriate signals are transferred from the system through the electrodes and into the appropriate tissue or neuronal site. Accordingly, the next section will discuss the various interfacing systems used by retinal implant groups with consideration to the various surgical alignment positions used by each group. The discussion has been limited to the research groups who have moved from preclinical research into human clinical trials.
Second Sight Medical Products (Epiretinal)
Second Sight Medical Products have clinically tested two device generations. The first generation device, Argus I [48, 49] , was implanted in six clinical trial patients. The Argus I is designed and used to perform basic object differentiation and motion tasks [13, 50] . It follows well-established platinum-silicone fabrication techniques. The Argus I retinal prosthesis features a 4 × 4 platinum electrode array suspended in a silicone carrier. The electrode array is made up of a series of platinum disk electrodes 260-520 µm in diameter, with center to center electrode pitch of 800 µm and evenly spaced over a retinal area of 2.84 × 2.84 mm or approximately 9.5°of visual angle. The electronics driving the array is located subdermally and connected to the electrode array via a subcutaneous cable. There is no external unit.
The Argus II [51, 52] retinal prosthesis developed for Second Sight's second round of clinical trials is a scaled-up version of the Argus I (Figure 24.8) . The Argus II features a 60-channel retinal MEA, an implanted coil for inductive power, and data transfer between an external unit and electronics unit fixed to the sclera of the eye. The external unit consists of a video processor, battery, and small camera and transmitter mounted on a pair of glasses. Connecting the array to the implanted electronics is a metallized polymer ribbon cable that penetrates the sclera in the pars plana [52] . The device is held against the retina using a retinal tack.
Intelligent Medical Implants AG (Epiretinal)
Designed for use in acute human trials, the Intelligent Medical Implants (IMI) AG retinal implant is implanted in the epiretinal location. Referred to as a microcontact film by the developing researchers [54] , the acute devices are 10 µm thick, 1 mm wide and 60 mm long thin-film electrode array manufactured using standard microfabrication methods. The implant consists of a visual processor mounted on a pair of glasses which communicates wirelessly with the retinal stimulator positioned on the retina. Power is provided by an inductive link between an external antenna and a episcleral receiver which communicates to the MEA by a transcleral cable. Data are communicated through an IR optical link. The stimulation microchip is positioned episclerally providing a 232-channel stimulus (microchip footprint of 22 m 2 ). The electrodes are coated in IrOx, and electrode diameters of 50 µm and 100 µm have been used as well as electrode diameters of 200 µm, and 360 µm. A hole in the end of the microcontact films and adjacent to the electrodes is used for retinal tack fixation in preclinical studies.
Retina implant AG (subretinal)
Combining both a microphotodiode array (MPDA) and thin-film techniques, the Alpha IMS subretinal implant developed by the Tubingen group [55, 56] is currently in Figure 24 .7 N-UNCD films prepared for a retinal prosthesis taken from [45] .
a second round of clinical trials [6, 57] . Designed to replace the function of degenerated photoreceptor cells directly by translating incident light falling onto the retina point by point, the Alpha IMS implant features a MPDA with 1500 individual light sensitive pixel-generating elements on a 20 µm thick polyimide foil also carrying 16 electrode test electrodes as a 4 × 4 quadruple array (Figure 24.9) . By incorporating the two technologies, the Alpha IMS subretinal implant allows for functional testing of multiple stimulation paradigms in one device. The device connects to an external power supply using a cable across the pigment epithelium, choroid, and sclera, and is then connected to a percutaneous plug via a subcutaneous connector and lead. The microphotodiodes use the intensity of light on the photodiode to adjust the stimulus pulse [58] .
EPI-RET GmbH (epiretinal)
Based in Germany, the EPIRET group has now developed three generations of retinal prostheses. The EPIRET 3 device, having now progressed to clinical trials, is fabricated using standard thin-film processes. The EPIRET 3 consists of two parts: (i) an extraocular unit mounted on a pair of glasses including a computer system and transmitter unit; and (ii) an intraocular unit comprising a polyimide thin-film structure supporting a receiver module and stimulating electrode array (Figure 24 .10). The electrode array features 25 stimulating electrodes fabricated from gold and coated with iridium oxide [22, 59] . The 100 µm electrodes are arranged in a hexagonal array with a center to center pitch of 500 µm. Power and data are transmitted using an inductive link from the transmitter positioned at the front of the eye to a received positioned in the intraocular lens.
Osaka University/NIDEK Co (suprachoroidal-transretinal)
Following a similar approach to Second Sight, the Osaka University/NIDEK Co. device is of platinum-silicone construction with 49 "bullet" shaped electrodes in a planar MEA. Each individual electrode is connected to an implanted stimulator via a coiled platinum wire. The array of platinum electrodes is supported by a silicone substrate designed to minimize surgical trauma. Each bullet shaped electrode is 0.5 mm in diameter with a center to center spacing of 0.7 mm. To date, two patients with retinitis pigmentosa (RP) have been acutely implanted with the NIDEK device [62] . Earlier devices developed by the NIDEK group for preclinical studies employed polyimide-based thin-film processes [63, 64] . The device comprises intraocular electronics whereby the microchips used to direct stimulus pulses to electrodes are placed on the reverse side of the stimulating electrode (Figure 24.11) . The merit in decreasing the distance between microchip and stimulating electrode is to decrease (eliminate in this case) the number and bulk of power and data lines, and the distance that they must travel through the human anatomy. This is achieved using a fabrication method known as flip-chip bonding. 
Boston Retinal Implant Group (epi/subretinal)
Although the Boston Retinal Implant Group (BRIG) now works on a subretinal device, initial prototype devices and clinical testing was performed epiretinally. In the early part of the 2000s, the BRIG conducted acute stimulation of five blind patients and one normally signted patient. [65, 66] . During these acute surgical trials, iterative changes to electrode geometry were based on feedback from electrical stimulation. [65] The device comprises a receiver coil on the sclera surface which communicates via a wire through the eye wall to the MEA and to an external transmitter coil positioned on the rim of a pair of glasses. Recently the BRIG has been developing a fully implantable epiretinal device for human trials. [24, [67] [68] [69] The device illustrated in Figure 24 .12 is intended to comprise 200 individually controlled stimulating electrodes powered wirelessly via an inductive link.
Bionic Vision Australia (suprachoroidal)
In 2012, three clinical trial patients were implanted with a prototype wide-view retinal prosthesis developed by the Bionic Vision Australia (BVA) consortium [70] . The prototype device, featuring thirty-five platinum electrodes, twenty individually accessible 600 µm diameter electrodes, thirteen 600 µm electrodes shorted together and two 2 mm return electrodes was developed to assess the safety efficacy of a suprachoroidal placement for a retinal prosthesis in humans. Earlier work [71] [72] [73] [74] conducted by the Bionics Institute in preclinical research led to the development of the device seen in Figure 24 .13 using platinum-silicone fabrication techniques. Individual insulated platinum wires are welded to each electrode and are coiled to form a helical cable. The device does not at present contain implantable electronics and instead connects to an external stimulator via a percutaneous pedestal secured behind the ear such that the external stimulator can access the electrodes directly, allowing greater control of electrical stimulation.
Engineering development -past and future
Optobionics (subretinal)
Developed by Alan and Vincent Chow, the Artificial Silicon Retina (ASR) microchip is a subretinal MEA comprising a 2 mm diameter silicon microchip with a reported thickness of 25 μm [75] . The microchip comprises individually isolated 5000 microphotodiode pixels (20 × 20 μm) with a 9 × 9 μm iridium oxide electrode bonded to each pixel. The device is powered solely by incident light without the need for any external components such as wires. The reported illumination is 800 foot-candles from a pixel current of 8-12 nA [75] . Although the ASR showed promising results from its pilot clinical trial, Optobionics is currently not undertaking any further clinical trials.
Seoul National University (suprachoroidal)
Also developing a suprachoroidal retinal prosthesis, the Korean team from the Seoul National University are delivering promising results in preclinical studies [76, 77] , The group are continuing to developing new fabrication techniques using liquid crystal polymers [78] to overcome the reported biostability issues with polyimide, which tends to absorb moisture and delaminate [79] . Chronic implantation of crystal polymer substrates have shown to be well tolerated by the eye with no damage to the neural retina after 3 months of implantation [76, 77] .
Bionic Vision Australia
The Bionic Vision Australia consortium is currently in the preclinical testing phase of two additional retinal electrode devices. The first prototype builds on the platinum-silicone fabrication methods developed in their first clinical device [70] . The device being explored is a 98-electrode retinal implant for suprachoroidal implantation advanced using laser patterning techniques [80] . In this work, a platinumsilicone device is fabricated as with a polyimide thin-film device, where a silicone elastomer is used as a base layer, platinum foil is then applied, and using a laser, stimulating electrodes and connection tacks are cut into the platinum foil. Excess platinum is removed, and silicone elastomer is spun-coated over the platinum as an insulation layer. Finally the stimulating electrodes are exposed by laser patterning. To further increase charge injection limits, the exposed electrodes can either be roughed by laser ablation, or coated with conducting polymers [47] . The second prototype device comprises a MEA made of diamond. The MEA is fabricated using microwave plasma enhanced deposition of insulating polycrystalline and conductive ultrananocrystalline diamond in order to produce areas on the array of known conductivity [43, 45, 81] . The MEA is produced using standard microfabrication technology, and accordingly multitudes of electrodes can be produced. The second-generation device is expected to have 1032 electrodes in a 16 × 16 array coupled directly to implanted microelectronics and housed in a hermetic diamond capsule.
Microelectronics to drive the MEA
MEAs cannot be thoroughly discussed without considering, albeit briefly, the electronics required to induce a stimulus in the MEA. Ideally, the microelectronics package is best used when intraocularly implanted as this is the best mechanism to prevent wires from transversing the eye wall. The key design considerations for the microelectronics are size, power consumption, and output; that is, the microelectronics needs to be able to drive enough current into the tissue to be able to excite a phosphene [82] . Size is often problematic. In the push for more stimulation electrodes, the microelectronics remains limited by the minimum required feature size of its electrode driving circuitry. Surgically, the entire implanted device, included the microelectronics package, is required to fit through an incision wound. This places some limitation on the maximum size which is probably no more than 5-6 mm 2 . Microelectronics are generally comprised of highly toxic materials such as copper, aluminum, and indium. Thus, in order to make the device fully implantable, hermetic housing is a crucial design consideration. There are generally two types of housing used at present: an encapsulating capsule, or a thin-film coating. Hard capsules are made of biocompatible or bioinert materials such as ceramics, metals such as titanium, and glass. The largest problems with having a secondary capsule are firstly that the capsule needs to be sealed within temperature limitations of the internal electronics, and secondly, that the capsule requires feedthroughs to enable the microelectronics to connect to the MEA. Thin-film coatings provide a less bulky alternative as the film will conform to the underlying microelectronics. However, the majority of thin-film coatings such as silicones do not provide a longterm hermetic seal [82] . Paralene, a conformal polymer, has been used as a thin-film coating in retinal devices, with a coated device holding its function after 14 months of implantation [83] .
Performance of retinal prostheses
Phosphenes
The term "phosphene" is defined as a visual percept which can be induced by mechanical, electrical, magnetic, or auditory stimulation to the eye without light having to enter the eye. In the case of retinal prostheses, phosphenes elicited through electrical stimulation of a single electrode are usually perceived as a whitish or yellowish flash of light, often without a discrete shape but sometimes with a welldefined shape. To this end, they have been reported to appear as points, spots, bars, or chaotic structures of both colored and colorless light [84] [85] [86] . Electrically induced phosphenes have rarely been defined as simple percepts. In some cases, phosphenes have been described as percepts that can appear darker than the patients' naturally perceived background light, sometimes with both bright and dark areas in the same phosphene and sometimes even in different colors. In terms of shape, phosphenes have typically been described to be roundish but can also be elongated, arc-like, or just "blob-like" without any form.
It is unclear as to what ultimately determines the perceptual properties of a phosphene; however, the brightness, shape, size, duration, and location of perceived phosphenes are well known to vary with the location and the number of electrodes stimulated in the retina, as well as the parameters used for electrical stimulation. Despite the complexities in phosphenes induced through electrical stimulation, they are considered to be the primitive building blocks of prosthetic vision that can be used to display an image akin to pixels on a computer display. It is thus generally accepted that a large number of non-overlapping phosphenes will result in improved resolution and better vision for a retinal prosthesis. Below we present some of the properties of phosphenes and the performance levels achievable with phosphene vision in blind humans described in the literature by the major retinal prosthesis companies and research groups.
Second Sight medical products (epiretinal)
Initial results by Humayun et al. from acute stimulation of the retina, using platinum wire electrodes under local anesthesia, provided the much-required proof of concept that localized phosphenes can be induced from focal epiretinal stimulation [2] . Patients in this study described the phosphenes as round, ring, line, or rectangle shapes that were the size of a pin, pea, or match head, and mostly yellow in color [2] . In a follow-up study using an array of platinum electrodes, it was reported that simple patterns such as continuous lines, the letter H, and a box shape could be perceived upon sequential stimulation of multiple electrodes [87] . Although most of the thresholds reported in their earlier study [2] were much above those considered safe for long-term stimulation, Humayun et al. posited that improvements in electrode design that reduced the distance between the electrodes and the retina, and careful selection waveform parameters would enable lower thresholds in the future. Subsequently, with the Argus I device [48, 49] , the group was able to demonstrate low threshold percepts and showed that long-term thresholds were dependent on impedance and distance of the electrode array from the retina, but not on electrode size and retinal thickness. Using just 16 electrodes present in this device, patients were able to perform simple object counting and object differentiation as well as some motion discrimination and orientation identification tasks [13, 50] .
To date, with the Argus I device implanted in six patients, the Argus II device in over 30 patients, and over 10 years of experience with chronic stimulation in blind humans, Second Sight have been able to establish themselves as the leaders in retinal prostheses. They are the only group to have developed a commercially available retinal prosthesis system that has been granted CE approval in Europe and HDE approval in the United States. Subjects implanted with the latest Argus II system containing 60 electrodes have been reported [3, 51] to be able to perform significantly better in object localization [88] , motion discrimination [51, 89, 90] , and discrimination of oriented gratings [91] with the system turned on than with it turned off, even two years after implantation [3] . In addition, patients have been able to identify different-sized shapes, both filled and outlined [92, 93] , are able to consistently read short sentences [94] , and are able to perceive complex patterns with intersecting lines [95] . The best visual acuity to date is found to be 20/1260 [3] . Recently, it was reported that patients can even perceive up to eight different combinations of colors depending upon the frequency of stimulation [96, 97] as well as simultaneous colors on two separate electrodes [97] . Numerous challenges still remain with regards to the fading of percepts in many patients [20] , the ability to place electrodes close enough to the retinal surface, stimulation of fibers of passage leading to arc-like percepts [98] , and being able to systematically control the brightness, shape, and size of phosphenes through appropriate modulation of stimulation parameters [86] .
Intelligent Medical Implants AG (Epiretinal)
A wireless powered 49-electrode implant dubbed the "learning encoder retinal prosthesis system" has been developed by this group [23] and was implanted in a total of four retinitis pigmentosa patients. [99] In at least one patient, follow-ups have been conducted over a period of nearly three years [14] . Thresholds were found to remain stable over several months of testing sessions and reported to be well under the safe limits of charge [16, 99] . Perceptions of simple patterns such as a vertical/horizontal bar or a cross and discriminability of individual phosphenes have been possible with stimulation of appropriate electrodes [99, 100] . A recent report by the group on acute stimulation in 20 patients under anesthesia using an MEA containing a range of electrode sizes indicated reliable threshold measurements ranging between 20 and 768 nC in 15 patients [101] . The large variability in thresholds in their study was attributed to a combination of varying degree of retinal degeneration, different electrode sizes, and varying distances between the electrode array and retina [101] . Patients mostly perceived phosphenes that were light in contrast to their background, with the exception of one patient who reported a dark phosphene [101] . Phosphenes were found to have a wide variety of described shapes ranging from simple percepts of a circle or ring to more complex shapes such as a hash mark or a fan-like arrangement of fluorescent tubes [101] . In functional assessment, the four patients were able to undertake basic localization tasks and recognize simple light patterns [102] .
Retina Implant AG (subretinal)
The first-generation device from Retina Implant AG was implanted in eight blind patients for a duration of 4 weeks, and in four more patients for a duration of 4 months [103] . The implanted system contained two parts, one a 4 × 4 electrode array that was directly accessed externally through a cable exiting the skin and the other an encapsulated microphotodiode chip with 1500 individual photodiodes each with its own amplifier circuitry and stimulation electrode, which was externally powered through the same cable [6] . Psychophysical results from direct stimulation of the 4 × 4 electrode array have been presented in Wilke et al. [103] , while results from task-based tests using the photodiode chip have been presented by Zrenner et al. [6] Using the 4 × 4 array, six of the patients were able to perceive phosphenes from both single and simultaneous multiple electrode stimulation; in a further two patients, activation of multiple electrodes was necessary to generate a phosphene; and in three patients no phosphenes were perceived. One subject withdrew consent from the study [103] . Unlike the abovementioned epiretinal studies, phosphenes implanted with the subretinal device were generally described as simple and tended to be yellowish round or oval-shaped percepts [103] . Thresholds ranged between 2.1 and 91.8 nC with most of the variance attributed to patients and individual electrodes within a patient [104] . Thresholds were also found to depend moderately on the number of electrodes stimulated simultaneously, time after implantation (particularly in the early days post implantation), pulse duration, pulse shape, and frequency [104] . A number of different patterns such as single lines of different orientations, parallel lines, geometric objects such as a triangle or square, and simple letters were shown to be perceived upon sequential stimulation of electrodes [103] .
However, because of the reported problem of perceptual fading upon repetitive stimulation of a single electrode [4, 6, 21] , inter-stimulus intervals for sequential stimulation have to be kept greater than 100 ms (<10 Hz). This problem of fading is believed to have been solved by the use of the photodiode array, as patients with this array are able to detect and identify grating patterns, letters, and everyday objects as complete entities, without needing to move the head [6] . It has been proposed that the reason that images do not fade with the photodiode array is because of saccadic eye movements that refresh the image and allow a different part of the photodiode array to be stimulated each time as the array moves synchronously with the eye [6] . This even enabled one patient in the study to be able to correctly name and describe objects such as a fork, knife, and different fruits with only 15% contrast [6] . In addition, this patient was able to localize and approach persons in a room freely as well, as to read large letters or complete words [6] . The group has been able to develop a second-generation device eliminating the need for an externalized cable. Power and data are now transmitted inductively via a subdermal retroauricular coil from which an internal cable leads to the photodiode chip in the subretinal space containing 1500 electrodes [5] . This new device has already been implanted into 10 patients as part of a multicenter international trial [5] . The best visual acuity found to date is 20/550, and one patient has had the implant for 1.25 years [5] .
EPI-RET GmbH (epiretinal)
The German-based EPIRET group has developed three generations of devices, the third of which (termed the EPIRET3 system) has advanced to clinical trials, and is completely intraocular with the electronics capsule replacing the lens, unlike the Second Sight design where the electronics capsule is attached to the scleral surface within the orbit [105] . This device was successfully implanted in six retinitis pigmentosa patients for a duration of 4 weeks and tested during three 1-hour stimulation sessions [15, 106] . Owing to the short duration of implantation, complex tasks involving the use of a camera were not tested and only basic psychophysical results are available [15] . All patients were successfully able to perceive phosphenes with thresholds below safe limits, albeit with a very wide range, similar to studies by Second Sight and Intelligent Medical Implants [15] . Patients were also able to discriminate and identify simple patterns generated on the stimulating array, such as oriented lines or a circle [15] . The group at present is believed to be working on a new-generation device with more electrodes and higher signal processing power [106] .
Osaka University/NIDEK Co (suprachoroidal-transretinal)
The suprachoroidal surgical approach was first proposed in 2004 by Kanda et al. [107] , and proof of concept that acute stimulation via this approach can result in phosphene perception in blind humans was shown in 2007 by Fujikado et al. [108] . Although the location of the implant is termed suprachoroidal, it is not located in the suprachoroidal space, but in a pocket within the sclera itself. This is in contrast to other groups also working towards a suprachoroidal approach but with an electrode array located in a pocket created in the cleavage plane between the sclera and the choroid [71-74, 109, 110] . Since their initial work, the group based in Japan has developed an electrode array containing 49 "bullet-shaped" platinum electrodes along with a 6 mm long platinum wire electrode that is implanted into the vitreous to serve as a monopolar return. The electrodes on the array are electrochemically etched to increase the effective surface area [111, 112] . An implantable decoder/stimulator linked to an inductive coil located subdermally behind the ear makes up the rest of the system [62] . A pilot study for a duration of 4 weeks with this device was recently conducted in two patients with retinitis pigmentosa, with 9 of the 49 electrodes tested in each patient [62] . Using the device, one patient was able to perceive phosphenes on six electrodes and the other patient on four electrodes with thresholds below the maximum tested current of 1 mA [62] . With the device coupled to a video camera, both patients performed significantly better than chance in object detection and discrimination tasks, while one patient was able to detect the direction of motion and grasp objects [62] .
Boston Retinal Implant Group (epi/subretinal)
Although the Boston group has been recently concentrating all efforts on a fully implantable subretinal device, for nearly a decade they worked on an epiretinal implant [113] . During this time, they were able to perform acute stimulation in five patients with severe retinitis pigmentosa and one normally sighted human [114, 115] . Phosphenes were elicited in three blind patients and in the normally sighted patient, with the lowest recorded threshold in the blind patients 4 times higher than in the normally sighted patient [115] . Sometimes, multiple phosphenes were perceived with single electrode stimulation [114] . Multiple electrode stimulation in a given pattern did not always induce the perception of the pattern, but most phosphenes were reproducible [114] . Since abandoning the epiretinal approach, the group has developed two generations of subretinal devices capable of chronic stimulation through over 256 electrodes, one for testing in animals and the other intended for humans [113] . Animal studies with full wireless devices have been ongoing for the past two years [113] . The group has recently set-up two companies, named Bionic Eye Technologies and Visus Technologies, to commercialize their technologies [116] .
Bionic Vision Australia (suprachoroidal)
Bionic Vision Australia has recently commenced pilot clinical trials in three RP patients using a suprachoroidally implanted platinum-silicone MEA device. The implanted patients have reportedly been able to see phosphenes [70] ; however, any further details of the pilot studies are yet to be reported.
Future thoughts
Although retinal prostheses are now a reality, several challenges remain to achieve useful vision that will assist in tasks of daily living and provide navigation, face recognition, and reading abilities for the blind. The biggest challenge is designing an appropriate stimulation strategy that will make clever use of primitive phosphenes to display the intended image. Massive efforts are under way globally to improve resolution through a combination of clever frontend vision processing, increasing the number of physical electrodes, placing electrodes as close as possible to the target neurons or using novel methods for electrical stimulation. Development of newer electrode materials, encapsulation technologies, surgical techniques, and image and signal processing as part of a multidisciplinary approach in the next 10 years will all help towards achieving the goal of restoring vision to the blind.
